Cell cycle dependence of ACE-2 explains downregulation in idiopathic pulmonary fibrosis
Open Access
- 25 October 2012
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 42 (1), 198-210
- https://doi.org/10.1183/09031936.00015612
Abstract
Alveolar epithelial type II cells, a major source of angiotensin-converting enzyme (ACE)-2 in the adult lung, are normally quiescent but actively proliferate in lung fibrosis and downregulate this protective enzyme. It was, therefore, hypothesised that ACE-2 expression might be related to cell cycle progression. To test this hypothesis, ACE-2 mRNA levels, protein levels and enzymatic activity were examined in fibrotic human lungs and in the alveolar epithelial cell lines A549 and MLE-12 studied at postconfluent (quiescent) versus subconfluent (proliferating) densities. ACE-2 mRNA, immunoreactive protein and enzymatic activity were all high in quiescent cells, but were severely downregulated or absent in actively proliferating cells. Upregulation of the enzyme in cells that were progressing to quiescence was completely inhibited by the transcription blocker actinomycin D or by SP600125, an inhibitor of c-Jun N-terminal kinase (JNK). In lung biopsy specimens obtained from patients with idiopathic pulmonary fibrosis, immunoreactive enzyme was absent in alveolar epithelia that were positive for proliferation markers, but was robustly expressed in alveolar epithelia devoid of proliferation markers. These data explain the loss of ACE-2 in lung fibrosis and demonstrate cell cycle-dependent regulation of this protective enzyme by a JNK-mediated transcriptional mechanism.Keywords
This publication has 33 references indexed in Scilit:
- Regulation of alveolar epithelial cell survival by the ACE-2/angiotensin 1–7/Mas axisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2011
- Angiotensin II and pulmonary fibrosis, a new twist on an old storyAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2011
- Novel therapeutic approaches for pulmonary fibrosisBritish Journal of Pharmacology, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- The Angiotensin-Converting Enzyme 2/Angiogenesis-(1–7)/Mas Axis Confers Cardiopulmonary Protection against Lung Fibrosis and Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Role of HIF-1α in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cellsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- Ectodomain shedding of angiotensin converting enzyme 2 in human airway epitheliaAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- JunD and HIF‐1α mediate transcriptional activation of angiotensinogen by TGF‐β1 in human lung fibroblastsThe FASEB Journal, 2009
- Regulation of ACE2 in cardiac myocytes and fibroblastsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2008